Impact BioMedical Inc. (IBO) stock
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $329.93MP/E –Yield –
Impact BioMedical operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Impact BioMedical's operating cash flow for the twelve months ending Jun 30, 2026 was -$508.00K. For fiscal 2025 it was -$1.89M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.89M | – |
| FY2024 | Dec 31, 2024 | -$2.85M | – |
| FY2023 | Dec 31, 2023 | -$2.85M | – |
| FY2022 | Dec 31, 2022 | -$2.24M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $470.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$464.00K | – |
| Q4 FY2025 | Dec 31, 2025 | $99.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$613.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$694.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$682.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$986.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$385.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$482.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$433.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$671.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$733.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$363.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$802.00K | – |
See a number that looks wrong?